Suchergebnisse - "Immunosuppressive Agents"

PubPharm (33)

1

Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults : A Chinese Multicenter Retrospective Study

enthalten in: American journal of nephrology | 2024

von Lan, L. | Lin, Y. | Yu, B. | +11

2

Treatment of Autoimmune Hepatitis

enthalten in: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | 2023

von Kim, J.

3

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease

enthalten in: BMC nephrology | 2021

von Liu, D. | Zhou, Z. | Wang, M. | +6

4

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

enthalten in: Advances in therapy | 2020

von Bowen, J. | Mehta, R. | Pelletier, C. | +4

5

Population pharmacokinetic analysis of intravenous busulfan : GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Sun, Y. | Huang, J. | Hao, C. | +6

6

Clinical review report : indication : indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, June 2020

CADTH common drug review

Version: Final.

7

Pharmacoeconomic review report : (UCB Canada Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapyCertolizumab pegol (Cimzia)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2020

CADTH common drug review

Version: Final.

8

Pharmacoeconomic review report : indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.)

Erschienen: Ottawa (ON), CADTH, June 2020

CADTH common drug review

Final (with redactions).

9

Belimumab treatment for adults with systemic lupus erythematosus : a review of clinical effectiveness, cost-effectiveness, and guidelines

Erschienen: Ottawa, CADTH, May 23, 2018

CADTH rapid response report: summary with critical appraisal

Version: 1.0.

von Chao, Y. | Adcock, L.

10

A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2017

von Caillard, S. | Cellot, E. | Dantal, J. | +20